이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

진행성 고형 종양이 있는 참가자의 GS-0201 단독 및 병용 연구

2026년 11월 10일 업데이트: Gilead Sciences

진행성 고형 종양이 있는 성인을 대상으로 단독 요법 및 병용 요법으로서 GS-0201의 안전성과 내약성을 평가하기 위한 1상 연구

The main goal of this first in human (FIH) study is to learn about the safety and dosing of GS-0201 when given alone or in combination with sacituzumab govitecan (SG) in participants with advanced solid tumors.

The primary objectives of this study are to:

  • To assess the safety and tolerability of GS-0201 as monotherapy and in combination with SG in participants with selected advanced solid tumors
  • To identify the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of GS-0201 as monotherapy and the MTD and/or the RP2D and dosing schedule of GS-0201 in combination with SG in participants with selected advanced solid tumors

연구 개요

연구 유형

중재적

등록 (추정된)

278

단계

  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

      • Gangnam-Gu, 대한민국, 06351
        • 모병
        • Samsung Medical Center
      • Goyang-si Gyeonggi-do, 대한민국, 10408
        • 모병
        • National Cancer Center - Korea
      • Seoul, 대한민국, 05505
        • 모병
        • Asan Medical Center
      • Seoul, 대한민국, 03722
        • 모병
        • Yonsei University Severance Hospital
      • Seoul, 대한민국, 03080
        • 모병
        • Samsung Medical Center
    • Massachusetts
      • Boston, Massachusetts, 미국, 02459
        • 모병
        • Dana-Farber Cancer Institute
    • New York
      • New York, New York, 미국, 10065
        • 모병
        • Memorial Sloan Kettering Cancer Center
    • Texas
      • Austin, Texas, 미국, 78758
        • 모병
        • NEXT Austin
      • Houston, Texas, 미국, 77030
        • 모병
        • The University of Texas MD Anderson Cancer Center
      • Irving, Texas, 미국, 75039
        • 모병
        • NEXT Dallas
      • Haifa, 이스라엘, 31096
        • 모병
        • Rambam Health Care Campus
      • Jerusalem, 이스라엘, 9112001
        • 모병
        • Hadassah Medical Center
      • Tel Aviv, 이스라엘, 6423906
        • 모병
        • Tel Aviv Sourasky Medical Center
      • Tel HaShomer, 이스라엘, 52621
        • 모병
        • Chaim Sheba Medical Center

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Able to understand and give written informed consent.

  • Assigned female or male at birth, 18 years of age or older, and meet the age of majority/adulthood per local regulations.

  • Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1.

  • Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria by investigator assessment.

  • Organ function requirements:

    • Adequate hematologic function
    • Adequate hepatic function
    • Creatinine clearance
    • Coagulation
  • Tissue requirement:

    • Parts A, B, C, and D:

      • Pre-treatment tumor tissue is required.
    • Parts A and C backfill biopsy cohorts:

      • Individuals must agree to fresh pre- and on-treatment biopsies.
  • Individuals assigned male at birth and individuals assigned female at birth and of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception

  • Willing and able to comply with the requirements and restrictions in this protocol

  • Part A (GS-0201 Monotherapy Dose Escalation) Inclusion Criteria:

    • Histologically/cytologically confirmed progressive/advanced solid tumors with selected molecular lesions.
    • Individuals must have received, been intolerant to, or been ineligible for all treatment known to confer clinical benefit or have a contraindication to receive the therapy
  • Part B (Dose Expansion) Inclusion Criteria:

    • Disease documented as:

    • Cohort B1:

      • Histologically or cytologically confirmed progressive/advanced selected solid tumor diagnoses harboring defined molecular lesions
      • Participants may potentially be required to forgo treatment with approved agent(s) to be able to participate in the study
    • Cohort B2:

      • Histologically or cytologically confirmed progressive/advanced solid tumor diagnoses harboring defined molecular lesions not included in Cohort B1
  • Part C (Dose Escalation) Inclusion Criteria:

    • Histologically or cytologically confirmed unresectable locally advanced/metastatic selected solid tumors
  • Part D (Dose Expansion) Inclusion Criteria:

    • Disease documented as:

    • Cohort D1:

      • Histologically or cytologically confirmed unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC)
    • Cohort D2:

      • Recurrent/persistent endometrial cancer

Exclusion Criteria:

  • Pregnant or lactating females

  • Known hypersensitivity to any of the study drugs, its metabolites, or formulation excipients

  • Requirement for ongoing therapy with or use of any prohibited medications described in the protocol

  • Individuals with myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or with findings suggestive of MDS/AML

  • Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of GS-0201

  • The therapies listed below within the specified timeframe:

    • Major surgery (excluding minor procedures, eg, placement of vascular access, gastrointestinal/biliary stent, biopsy) < 4 weeks prior to planned Cycle 1 Day 1
    • Immunotherapy or biologic therapy < 21 days prior to planned Cycle 1 Day 1
    • Chemotherapy < 14 days prior to planned Cycle 1 Day 1, or < 42 days for mitomycin or nitrosoureas
    • Targeted small molecule therapy < 14 days prior to planned Cycle 1 Day 1
    • Receipt of experimental therapy within 21 days or 5 experimental treatment half-lives (whichever is longer) prior to planned Cycle 1 Day 1
    • Hormonal or other adjunctive therapy for cancers other than the cancer under evaluation in this study that started < 14 days prior to planned Cycle 1 Day 1 are not permitted. Hormonal therapy, bisphosphonates, somatostatin analogues, and leuprolide are permitted if started ≥ 14 days prior to planned Cycle 1 Day 1
    • Radiotherapy within 2 weeks prior to planned Cycle 1 Day 1 and the radiation is not administered to a target lesion
    • Any prior allogeneic tissue/solid organ transplantation, including allogeneic hematopoietic stem cell transplantation. Individuals with a history of autologous hematopoietic stem cell transplantation are also excluded
  • Have not recovered (ie, Grade 1 or lower) from AEs due to a previously administered agent

  • Prior treatment with approved or experimental prohibited agents as detailed in the protocol.

  • Diagnosis of immunodeficiency, either primary or acquired, or requires systemic corticosteroids (> 10 mg of prednisone daily, or equivalent). However, replacement doses, topical, ophthalmologic, and inhalational steroids are permitted

  • Have an active second malignancy

  • Have known active central nervous system (CNS) metastases

  • Individuals with carcinomatous meningitis or primary CNS tumors are excluded regardless of clinical stability

  • Meet any of the following criteria for cardiac disease:

    • Myocardial infarction or unstable angina pectoris within 6 months of enrollment
    • History of serious ventricular arrhythmia (ie, ventricular tachycardia or ventricular fibrillation), high-grade atrioventricular block, or other cardiac arrhythmias requiring antiarrhythmic medications (except for atrial fibrillation that is well controlled with antiarrhythmic medication)
    • QT interval > 470 msec
    • New York Heart Association Class III or greater congestive heart failure or known left ventricular ejection fraction less than 40%
  • Meet any of the following infectious criteria:

    • Have active serious infection requiring antimicrobials
    • Have active hepatitis B virus (HBV) or hepatitis C virus (HCV), or HIV. In individuals with a history of HBV or HCV, individuals with detectable viral loads will be excluded
    • Individuals who test positive for hepatitis B surface antigen. Individuals who test positive for hepatitis B core antibody are eligible with a negative HBV DNA by quantitative Polymerase chain reaction (PCR)
    • Individuals who test positive for HCV antibody. Individuals who test positive for HCV antibody are eligible with a negative HCV RNA by quantitative PCR
    • Individuals who test positive for HIV antibody
  • History of pneumonitis requiring treatment with corticosteroids, interstitial lung disease, or radiation pneumonitis requiring steroids

  • Symptomatic ascites or pleural effusion

  • Have other concurrent medical or psychiatric conditions that, in the investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations

  • Any medical condition that, in the investigator's or sponsor's opinion, poses an undue risk to the individuals participation in the study

  • Use of any live vaccines against infectious diseases within 4 weeks (28 days) of initiation of study drug(s) (inactivated, viral vector vaccines, and messenger RNA (mRNA) vaccines are allowed; seasonal vaccines should be up to date prior to planned Cycle 1 Day 1)

  • Parts C (Dose Escalation) and D (Dose Expansion): Combination Cohorts:

    • Individuals with active chronic inflammatory bowel disease (ulcerative colitis, Crohn disease) and individuals with a history of bowel obstruction or gastrointestinal perforation within 6 months prior to planned Cycle 1 Day 1
    • Individuals who previously received topoisomerase 1 inhibitors or antibody-drug conjugates containing a topoisomerase 1 inhibitor
    • Known severe intolerance or life-threatening hypersensitivity reactions to humanized monoclonal antibodies or intravenous (IV) immunoglobulin preparations; any history of anaphylaxis; history of human anti-human antibody response

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위화되지 않음
  • 중재 모델: 순차적 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Part A: GS-0201 Monotherapy Dose Escalation

Participants will receive escalating doses of GS-0201 monotherapy, until disease progression, or until the participant meets other study drug discontinuation criteria as specified in protocol or up to 105 weeks, whichever occurs first.

Pill administered orally

실험적: Part B: Cohort B1: GS-0201 Monotherapy Dose Expansion

Participants with selected breast cancer indication will receive GS-0201 monotherapy at the recommended dose for expansion.

Pill administered orally

실험적: Part B: Cohort B2: GS-0201 Monotherapy Dose Expansion

Participants with selected indications not included in cohort B1 will receive GS-0201 monotherapy at the recommended dose for expansion.

Pill administered orally

실험적: Part C: Dose Escalation: GS-0201 + Sacituzumab Govitecan (SG)

Participants will receive escalating doses of GS-0201 in combination with SG, until disease progression, or until the participant meets other study drug discontinuation criteria as specified in protocol or up to 105 weeks, whichever occurs first.

Pill administered orally

Administered intravenously

다른 이름들:
  • IMMU-132
  • GS-0132
  • 트로델비™
실험적: Part D: Cohort D1: Dose Expansion: GS-0201 + SG

Participants with confirmed unresectable locally advanced or metastatic triple negative breast cancer (mTNBC) will receive GS-0201 at the recommended Phase 2 dose (RP2D) in combination with SG.

Pill administered orally

Administered intravenously

다른 이름들:
  • IMMU-132
  • GS-0132
  • 트로델비™
실험적: Part D: Cohort D2: Dose Expansion: GS-0201 + SG

Participants with recurrent/persistent endometrial cancer will receive GS-0201 at the recommended Phase 2 dose (RP2D) in combination with SG.

Pill administered orally

Administered intravenously

다른 이름들:
  • IMMU-132
  • GS-0132
  • 트로델비™

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
부작용(AE) 및 심각한 부작용(SAE)이 발생한 참가자의 비율
기간: 첫 번째 접종은 마지막 접종 후 최대 30일까지입니다(최대 약 109주).
첫 번째 접종은 마지막 접종 후 최대 30일까지입니다(최대 약 109주).
실험실 이상 발생률
기간: 첫 번째 접종은 마지막 접종 후 최대 30일까지입니다(최대 약 109주).
첫 번째 접종은 마지막 접종 후 최대 30일까지입니다(최대 약 109주).
The Number of Participants with Dose Limiting Toxicities (DLTs) During Dose Escalation
기간: First dose up to 30 days post last dose (Up to approximately 109 weeks).

DLTs are defined as any of the following treatment-emergent adverse events (AEs) regardless of attribution (graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0), unless clearly related to an underlying disease or extraneous causes, with onset within the DLT-evaluation period for the corresponding dose.

First dose up to 30 days post last dose (Up to approximately 109 weeks).

2차 결과 측정

결과 측정
측정값 설명
기간
GS-0201 혈장 농도
기간: 치료 종료 시까지(최대 105주) 투여 전 및 투여 후
치료 종료 시까지(최대 105주) 투여 전 및 투여 후
사시투주맙 고비테칸(SG) 혈청 농도(파트 C 및 D만 해당)
기간: 치료 종료 시까지(최대 105주) 투여 전 및 투여 후
치료 종료 시까지(최대 105주) 투여 전 및 투여 후
Pharmacokinetic (PK) Parameter: Area Under the Concentration (AUC)0-24 of GS-0201
기간: Predose and postdose up to end of treatment (up to 105 weeks)

AUC0-24 is defined as the concentration of drug over time between time 0 and time 24 hours.

Predose and postdose up to end of treatment (up to 105 weeks)
PK Parameter: Cmax of GS-0201
기간: Predose and postdose up to end of treatment (up to 105 weeks)

Cmax is defined as the maximum observed drug concentration.

Predose and postdose up to end of treatment (up to 105 weeks)
PK Parameter: Tmax of GS-0201
기간: Predose and postdose up to end of treatment (up to 105 weeks)

Tmax is defined as the time to maximum observed concentration.

Predose and postdose up to end of treatment (up to 105 weeks)
PK Parameter: AUC0-168 of SG (Parts C and D only)
기간: Predose and postdose up to end of treatment (up to 105 weeks)

AUC0-168 is defined as the concentration of drug over time between time 0 and time 168 hours.

Predose and postdose up to end of treatment (up to 105 weeks)
PK Parameter: Cmax of SG (Parts C and D only)
기간: Predose and postdose up to end of treatment (up to 105 weeks)

Cmax is defined as the maximum observed drug concentration.

Predose and postdose up to end of treatment (up to 105 weeks)
PK Parameter: Tmax of SG (Parts C and D only)
기간: Predose and postdose up to end of treatment (up to 105 weeks)

Tmax is defined as the time to maximum observed concentration.

Predose and postdose up to end of treatment (up to 105 weeks)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 연구 책임자: Gilead Study Director, Gilead Sciences

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2024년 1월 9일

기본 완료 (추정된)

2028년 9월 1일

연구 완료 (추정된)

2028년 9월 1일

연구 등록 날짜

최초 제출

2023년 12월 4일

QC 기준을 충족하는 최초 제출

2023년 12월 4일

처음 게시됨 (실제)

2023년 12월 12일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 12일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 10일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

추가 관련 MeSH 약관

기타 연구 ID 번호

  • GS-US-686-6854

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다